Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amalia M Issa

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Annals of Translational Medicine|January 9, 2023
Cost-effectiveness of precision molecular diagnostic tests for stage II colorectal cancerVivek S Chaudhari, Amalia M Issa
Cancer|February 24, 2012
Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic modelMo Yang, Suja Rajan, Amalia M Issa
Clinical Pharmacology in Drug Development|November 4, 2025
What Does an Editor Do in 2025?Amalia M Issa, Michael Fossler, Vijay V Upreti
The British Journal of Ophthalmology|September 4, 2010
The quality of pharmacoeconomic evaluations of age-related macular degeneration therapeutics: a systematic review and quantitative appraisal of the evidenceWilliam J Foster, Waqas Tufail, Amalia M Issa
Expert Review of Molecular Diagnostics|December 6, 2014
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidenceAmalia M Issa, Vivek S Chaudhari, Gary E Marchant
Personalized Medicine|May 18, 2018
A national study of breast and colorectal cancer patients' decision-making for novel personalized medicine genomic diagnosticsAmalia M Issa, Waqas Tufail, Nelson Atehortua, et al.
Personalized Medicine|July 5, 2022
Evaluating the quality of the economic evidence in colorectal cancer genomics studiesVivek S Chaudhari, Kanchan C Hole, Amalia M Issa
Nature Reviews. Drug Discovery|May 24, 2006
Diagnostics and biomarker development: priming the pipelineKathryn A Phillips, Stephanie Van Bebber, Amalia M Issa
Personalized Medicine|May 12, 2018
Big data in the era of precision medicine: big promise or big liability?Amalia M Issa, Gary E Marchant, Douglas Campos-Outcalt
Expert Review of Pharmacoeconomics & Outcomes Research|October 22, 2013
The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidenceMo Yang, Dhaval S Patel, Waqas Tufail, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Annals of Translational Medicine|January 9, 2023
Cost-effectiveness of precision molecular diagnostic tests for stage II colorectal cancerVivek S Chaudhari, Amalia M Issa
Cancer|February 24, 2012
Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic modelMo Yang, Suja Rajan, Amalia M Issa
Clinical Pharmacology in Drug Development|November 4, 2025
What Does an Editor Do in 2025?Amalia M Issa, Michael Fossler, Vijay V Upreti
The British Journal of Ophthalmology|September 4, 2010
The quality of pharmacoeconomic evaluations of age-related macular degeneration therapeutics: a systematic review and quantitative appraisal of the evidenceWilliam J Foster, Waqas Tufail, Amalia M Issa
Expert Review of Molecular Diagnostics|December 6, 2014
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidenceAmalia M Issa, Vivek S Chaudhari, Gary E Marchant
Personalized Medicine|May 18, 2018
A national study of breast and colorectal cancer patients' decision-making for novel personalized medicine genomic diagnosticsAmalia M Issa, Waqas Tufail, Nelson Atehortua, et al.
Personalized Medicine|July 5, 2022
Evaluating the quality of the economic evidence in colorectal cancer genomics studiesVivek S Chaudhari, Kanchan C Hole, Amalia M Issa
Nature Reviews. Drug Discovery|May 24, 2006
Diagnostics and biomarker development: priming the pipelineKathryn A Phillips, Stephanie Van Bebber, Amalia M Issa
Personalized Medicine|May 12, 2018
Big data in the era of precision medicine: big promise or big liability?Amalia M Issa, Gary E Marchant, Douglas Campos-Outcalt
Expert Review of Pharmacoeconomics & Outcomes Research|October 22, 2013
The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidenceMo Yang, Dhaval S Patel, Waqas Tufail, et al.
Pageof 6